HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
SDZ GLC 756
a novel octahydrobenzoquinoline
Also Known As:
GLC 756; GLC-756; SDZ GLC-756
Networked:
3
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Quinolines: 146
SDZ GLC 756: 3
Experts
1.
Court, M
: 1 article (11/2005)
2.
Germann, P G
: 1 article (11/2005)
3.
Laengle, U W
: 1 article (11/2005)
4.
Markstein, R
: 1 article (11/2005)
5.
Nogues, V
: 1 article (11/2005)
6.
Roman, D
: 1 article (11/2005)
Related Diseases
1.
Glaucoma
01/01/1996 - "
The simultaneous D-1 antagonistic and D-2 agonistic properties of SDZ GLC-756 may provide a new pharmacological approach to the treatment of glaucoma, which deserves further investigation.
"
09/01/1995 - "
The simultaneous D-1 antagonistic and D-2 agonistic properties of SDZ GLC-756 may provide a new pharmacologic approach to treating glaucoma and ocular hypertension, which deserves further investigation.
"
09/01/1995 - "
The novel dopamine D-1 antagonist and D-2 agonist, SDZ GLC-756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma.
"
09/01/1995 - "
In glaucoma patients the trial was designed as a crossover study administering SDZ GLC-756 (0.1%) eye drops and vehicle alone (control) to one eye in 12 patients with open-angle glaucoma or ocular hypertension.
"
2.
Ocular Hypertension (Glaucoma, Suspect)
09/01/1995 - "
The simultaneous D-1 antagonistic and D-2 agonistic properties of SDZ GLC-756 may provide a new pharmacologic approach to treating glaucoma and ocular hypertension, which deserves further investigation.
"
09/01/1995 - "
To investigate the intraocular pressure (IOP)-reducing effect and side effects of SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, in control subjects and patients with open-angle glaucoma or ocular hypertension.
"
09/01/1995 - "
In glaucoma patients the trial was designed as a crossover study administering SDZ GLC-756 (0.1%) eye drops and vehicle alone (control) to one eye in 12 patients with open-angle glaucoma or ocular hypertension.
"
3.
Open-Angle Glaucoma (Glaucoma, Open Angle)
09/01/1995 - "
To investigate the intraocular pressure (IOP)-reducing effect and side effects of SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, in control subjects and patients with open-angle glaucoma or ocular hypertension.
"
09/01/1995 - "
In glaucoma patients the trial was designed as a crossover study administering SDZ GLC-756 (0.1%) eye drops and vehicle alone (control) to one eye in 12 patients with open-angle glaucoma or ocular hypertension.
"
4.
Uveitis
11/01/2005 - "
GLC 756, a novel mixed dopamine D2 receptor agonist and D1 receptor antagonist, and timolol a beta-adrenoceptor antagonist using endotoxin-induced uveitis (EIU) and arthritis in rats as an in vivo model.
"
5.
Arthritis (Polyarthritis)
11/01/2005 - "
GLC 756, a novel mixed dopamine D2 receptor agonist and D1 receptor antagonist, and timolol a beta-adrenoceptor antagonist using endotoxin-induced uveitis (EIU) and arthritis in rats as an in vivo model.
"
Related Drugs and Biologics
1.
Ophthalmic Solutions (Eye Drops)
2.
Dopamine D2 Receptors (Dopamine D2 Receptor)
3.
Timolol (Blocadren)
4.
Endotoxins
5.
Dopamine (Intropin)
6.
Adrenergic beta-Antagonists (beta-Adrenergic Blocking Agents)